摘要
丙型肝炎病毒感染是一个全球性的公共卫生问题。干扰素治疗方案的出现让慢性丙型肝炎的治疗出现了转机,然而这些药物仍然无法满足广大丙型肝炎患者治疗的需求,很多患者因为有干扰素禁忌证,无法耐受不良反应,干扰素治疗无应答而无法得到良好的抗病毒治疗。但直接抗病毒药物的出现却给这些慢性丙型肝炎患者带来了福音。本文就索菲布韦治疗丙型肝炎的研究进展进行综述。
Hepatitis C virus(HCV) infection is a serious problem worldwide, and the use of interferon-based therapy has made things different. But this still could not help some other patients who have contraindications, those patients can’t bear the side effects or even have no response after the treatment of interferon. Though this is tough for those patients, the appearance of direct-acting antiviral agents makes things different. In particular, sofosbuvir, a nucleotide-based NS5 B inhibitor, comes to market perfectly is of vital importance to the treatment development.
出处
《中华临床医师杂志（电子版）》
CAS
2016年第23期3650-3653,共4页
Chinese Journal of Clinicians(Electronic Edition)
关键词
肝炎
丙型
慢性
抗病毒药
索菲布韦
Hepatitis C
chronic
Antiviral agents
Sofosbuvir
